Cargando…

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET

BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Notni, Johannes, Pohle, Karolin, Wester, Hans-Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538506/
https://www.ncbi.nlm.nih.gov/pubmed/22682112
http://dx.doi.org/10.1186/2191-219X-2-28
_version_ 1782254950195134464
author Notni, Johannes
Pohle, Karolin
Wester, Hans-Jürgen
author_facet Notni, Johannes
Pohle, Karolin
Wester, Hans-Jürgen
author_sort Notni, Johannes
collection PubMed
description BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have been shown to possess superior (68)Ga binding ability. Here, we report on the efficiency, reproducibility, and achievable specific activity for fully automated (68)Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates. FINDINGS: Compared to NOTA- and DOTA-peptides, achievable specific activity (A(S)) for TRAP-peptide is approximately 10 and 20 times higher, respectively. A(S) values in the range of 5,000 GBq/μmol were routinely obtained using 1 GBq of (68)Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate. The TRAP-peptide could be (68)Ga-labeled with excellent reproducibility and > 95% radiochemical yield for precursor amounts as low as 1 nmol. CONCLUSIONS: High (68)Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures. The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass content in tracer formulations.
format Online
Article
Text
id pubmed-3538506
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-35385062013-01-08 Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET Notni, Johannes Pohle, Karolin Wester, Hans-Jürgen EJNMMI Res Short Communication BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have been shown to possess superior (68)Ga binding ability. Here, we report on the efficiency, reproducibility, and achievable specific activity for fully automated (68)Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates. FINDINGS: Compared to NOTA- and DOTA-peptides, achievable specific activity (A(S)) for TRAP-peptide is approximately 10 and 20 times higher, respectively. A(S) values in the range of 5,000 GBq/μmol were routinely obtained using 1 GBq of (68)Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate. The TRAP-peptide could be (68)Ga-labeled with excellent reproducibility and > 95% radiochemical yield for precursor amounts as low as 1 nmol. CONCLUSIONS: High (68)Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures. The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass content in tracer formulations. Springer 2012-06-09 /pmc/articles/PMC3538506/ /pubmed/22682112 http://dx.doi.org/10.1186/2191-219X-2-28 Text en Copyright ©2012 Notni et al. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Notni, Johannes
Pohle, Karolin
Wester, Hans-Jürgen
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title_full Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title_fullStr Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title_full_unstemmed Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title_short Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
title_sort comparative gallium-68 labeling of trap-, nota-, and dota-peptides: practical consequences for the future of gallium-68-pet
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538506/
https://www.ncbi.nlm.nih.gov/pubmed/22682112
http://dx.doi.org/10.1186/2191-219X-2-28
work_keys_str_mv AT notnijohannes comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet
AT pohlekarolin comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet
AT westerhansjurgen comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet